Abstracts tagged "pharmacokinetics and systemic lupus erythematosus (SLE)"

Abstract Number: 2592 • 2017 ACR/ARHP Annual Meeting
Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Intravenous Anifrolumab in Healthy Volunteers
Raj Tummala¹, Tomas Rouse², Anna Berglind² and Linda Santiago³, ¹AstraZeneca, Gaithersburg, MD, ²AstraZeneca, Gothenberg, Sweden, ³MedImmune, LLC, Mountain View, CA
Background/Purpose: Anifrolumab is a fully human anti–interferon-ɑ receptor 1 monoclonal antibody in Phase III development as an intravenous (IV) therapeutic for systemic lupus erythematosus (SLE).…
Abstract Number: 761 • 2016 ACR/ARHP Annual Meeting
Exposure-Response Analysis for Selection of Optimal Dosage Regimen of Anifrolumab in Patients with Systemic Lupus Erythematosus
L Santiago¹, B Wang², P Brohawn², L Wang², G Illei² and L Roskos², ¹MedImmune, Mountain View, CA, ²MedImmune, Gaithersburg, MD
Background/Purpose: Anifrolumab is a fully human IgG1 monoclonal antibody directed against subunit 1 of the type I interferon–α receptor (IFNAR1) currently in development for the…
Abstract Number: 774 • 2016 ACR/ARHP Annual Meeting
BIIB059, an Anti-BDCA2 Monoclonal Antibody, Demonstrates Acceptable Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamic (PD) Effects in a Phase 1 Study with Single Ascending Doses (SAD) in Healthy Volunteers
David Martin, Lauren Stevenson, Pratapa Prasad, Karen Smirnakis, Amy Kao, Dania Rabah, Wenting Wang and Nathalie Franchimont, Biogen, Cambridge, MA
Background/Purpose: Type I interferons (IFN-I) are implicated in the pathogenesis of systemic lupus erythematosus (SLE). In SLE, immune complexes stimulate plasmacytoid dendritic cells (pDCs) to…
Abstract Number: 1800 • 2015 ACR/ARHP Annual Meeting
A Novel Anti-CD28 Domain Antibody Antagonist Shows a Favorable Pharmacokinetic, Pharmacodynamic and Safety Profile
R Shi¹, M Honczarenko¹, S Zhang², CA Fleener³, J Mora¹, S Lee¹, X Liu¹, DE Shevell¹, Z Yang¹, H Wang¹ and B Murthy¹, ¹Bristol-Myers Squibb, Princeton, NJ, ²GlaxoSmithKline, King of Prussia, PA, ³Pfizer Inc, Groton, CT
Background/Purpose: Antagonism of the CD28 costimulation receptor is thought to block T-cell activation, making this a promising target for the treatment of many autoimmune diseases,…
Abstract Number: 1822 • 2015 ACR/ARHP Annual Meeting
Pharmacokinetics of the Selective B-Cell Lymphoma-2 (Bcl-2) Inhibitor, ABT-199, in Female Subjects with Systemic Lupus Erythromatosus
Mukul Minocha¹, Shekman Wong², Jiewei Zeng², Peng Lu³, Jeroen Medema² and Ahmed Othman⁴, ¹Clinical Pharmacology and Pharmacometrics, AbbVie, North Chicago, IL, ²AbbVie Inc., North Chicago, IL, ³AbbVie Inc., Worcester, MA, ⁴AbbVie, North Chicago, IL
Background/Purpose: Selective Inhibition of Bcl-2 pathway may offer clinical efficacy in Systemic Lupus Erythromatosus (SLE) by restoring apoptosis in autoreactive cells, which may lead to…
Abstract Number: 2838 • 2014 ACR/ARHP Annual Meeting
Exploratory Analysis of Pharmacokinetic Effects of Atacicept in Patients with Moderate to Severe Systemic Lupus Erythematosus
David Wofsy¹, Caroline Gordon², Yong Li³, Stephen D. Wax⁴ and David Isenberg⁵, ¹Division of Rheumatology, University of California, San Francisco, CA, ²Rheumatology Research Group, School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, ³R&D Global BioStatistics, EMD Serono, Billerica, MA, ⁴Global Clinical Development Center - Immunology, EMD Serono Inc, Rockland, MA, ⁵Centre for Rheumatology Research, University College Hospital London, London, United Kingdom
Background/Purpose: Atacicept is a fusion protein that inhibits B-cell stimulating factors BLyS and APRIL. We previously reported the clinical effects of atacicept in lupus patients…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].